首页> 外文期刊>European review for medical and pharmacological sciences. >Ethical and medico-legal remarks on uterus transplantation: may it solve uterine factor infertility?
【24h】

Ethical and medico-legal remarks on uterus transplantation: may it solve uterine factor infertility?

机译:对子宫移植的伦理和药物法律言论:可以解决子宫因子不孕症吗?

获取原文
           

摘要

Uterus transplantation was firstly tested with animal trials sixty-five years ago. Despite several successful attempts in human subjects, the different procedures still lay at the experimental stage, in need of further studies and investigations before they can be considered as standard clinical practices. Uterus transplant cannot be regarded as a life-saving procedure, but rather a method to restore woman ability to procreate, when lost, thus improving her quality of life. Uterus transplant is a complex surgical procedure and presents significant health threats. Medical staff should therefore always obtain informed consent from patients, emphasizing such risks. Before that, women undergoing uterine transplants should be thoroughly informed about the hazards inherent to the procedure and especially about the dangers of immunosuppressant drugs, administered after the surgery which may injure the fetus, eventually formed in the restored organ and even lead to its death, thus nullifying the purpose of the transplant itself. Therefore, the risk-benefit ratio of uterus transplantation needs to be carefully assessed and described.
机译:先后六十五年前首先用动物试验进行了子宫移植。尽管人类受试者有几次成功的尝试,但不同的程序仍然在实验阶段奠定了需要进一步的研究和调查,并且在他们可以被视为标准的临床实践之前。子宫移植不能被视为拯救生命的程序,而是一种恢复妇女能力的方法,丢失时,损失,从而提高了她的生活质量。子宫移植是一种复杂的外科手术,并提出了重大的健康威胁。因此,医务人员应该总是从患者获得知情同意,强调这些风险。在此之前,应彻底了解接受子宫移植的妇女对手术治疗的危害,特别是免疫抑制药物的危险,这些危害可能造成伤害胎儿,最终在恢复的器官中形成,甚至导致其死亡,从而使移植本身的目的无效。因此,需要仔细评估和描述子宫移植的风险效益比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号